Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jawahar Mehta to Cardiovascular Diseases

This is a "connection" page, showing publications Jawahar Mehta has written about Cardiovascular Diseases.

 
Connection Strength
  
 
 
6.132
  
  1. Wang X, Liu L, Zhai L, Palade P, Wang X, Mehta JL. Direct Impact of PCSK9 on SMC Senescence and Apoptosis: A New Focus in Cardiovascular Diseases. Arterioscler Thromb Vasc Biol. 2024 07; 44(7):1491-1496.
    View in: PubMed
    Score: 0.698
  2. Barill? F, Bassareo PP, Calcaterra G, Romeo F, Mehta JL. Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications. J Cardiovasc Med (Hagerstown). 2020 09; 21(9):630-633.
    View in: PubMed
    Score: 0.536
  3. Romeo F, Calcaterra G, Barilla F, Mehta JL. Coronavirus disease 2019 infection and the cardiovascular system. J Cardiovasc Med (Hagerstown). 2020 06; 21(6):403-405.
    View in: PubMed
    Score: 0.527
  4. Mehta JL. Suicide, Depression, and Cardiovascular Disease. JACC Heart Fail. 2020 06; 8(6):519.
    View in: PubMed
    Score: 0.527
  5. Saad M, Salehi N, Ding Z, Mehta JL. Blood pressure target in diabetics: how low is too low? Eur Heart J. 2019 07 01; 40(25):2044-2046.
    View in: PubMed
    Score: 0.494
  6. Rochlani Y, Kattoor AJ, Pothineni NV, Palagiri RDR, Romeo F, Mehta JL. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. Am J Cardiol. 2017 Oct 01; 120(7):1122-1128.
    View in: PubMed
    Score: 0.431
  7. Mainali P, Pant S, Rodriguez AP, Deshmukh A, Mehta JL. Tobacco and cardiovascular health. Cardiovasc Toxicol. 2015 Apr; 15(2):107-16.
    View in: PubMed
    Score: 0.368
  8. Dai Y, Dai D, Mercanti F, Ding Z, Wang X, Mehta JL. Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. Acta Diabetol. 2013 Dec; 50(6):827-35.
    View in: PubMed
    Score: 0.326
  9. Mehta JL, Khaidakov M, Hermonat PL, Mitra S, Wang X, Novelli G, Sawamura T. LOX-1: a new target for therapy for cardiovascular diseases. Cardiovasc Drugs Ther. 2011 Oct; 25(5):495-500.
    View in: PubMed
    Score: 0.289
  10. Bansal D, Mehta JL. Current approaches to cardiovascular disease risk assessment. Indian Heart J. 2008 Mar-Apr; 60(2 Suppl B):B19-22.
    View in: PubMed
    Score: 0.225
  11. Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol. 2006 Oct 01; 98(7):923-8.
    View in: PubMed
    Score: 0.202
  12. Sepulveda JL, Mehta JL. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol. 2005 Sep; 20(5):407-16.
    View in: PubMed
    Score: 0.189
  13. Schr?r K, Mehta P, Mehta JL. Cardiovascular risk of selective cyclooxygenase-2 inhibitors. J Cardiovasc Pharmacol Ther. 2005 Jun; 10(2):95-101.
    View in: PubMed
    Score: 0.186
  14. Liu G, Yu X, Cui C, Li X, Wang T, Palade PT, Mehta JL, Wang X. The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism. Acta Physiol (Oxf). 2025 Feb; 241(2):e14272.
    View in: PubMed
    Score: 0.182
  15. Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol. 2004 Sep; 19(5):488-93.
    View in: PubMed
    Score: 0.177
  16. Calcaterra G, Bassareo PP, Spaccarotella CA, Barill? F, Sciomer S, Vadal? G, de Gregorio C, Romeo F, Mehta JL, Mattioli AV. The long-term cardiovascular impairment of COVID 19: need for clarity in definition and terminology. Minerva Cardiol Angiol. 2024 Feb; 72(1):24-31.
    View in: PubMed
    Score: 0.165
  17. Cheng W, Cui C, Liu G, Ye C, Shao F, Bagchi AK, Mehta JL, Wang X. NF-?B, A Potential Therapeutic Target in Cardiovascular Diseases. Cardiovasc Drugs Ther. 2023 06; 37(3):571-584.
    View in: PubMed
    Score: 0.152
  18. Jain N, Hunt SL, Cui H, Phadnis MA, Mahnken JD, Shireman TI, Dai J, Mehta JL, Rasu RS. Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovasc Drugs Ther. 2019 10; 33(5):511-521.
    View in: PubMed
    Score: 0.126
  19. Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. 2018 01 08; 113(1):5.
    View in: PubMed
    Score: 0.111
  20. Jensen HA, Mehta JL. Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis. Expert Rev Cardiovasc Ther. 2016 Sep; 14(9):1021-33.
    View in: PubMed
    Score: 0.101
  21. Yan M, Mehta JL, Zhang W, Hu C. LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications. Cardiovasc Drugs Ther. 2011 Oct; 25(5):451-9.
    View in: PubMed
    Score: 0.072
  22. Mango R, Vecchione L, Raso B, Borgiani P, Brunetti E, Mehta JL, Lauro R, Romeo F, Novelli G. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. Expert Opin Pharmacother. 2005 Dec; 6(15):2565-76.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.